Clinical Trial Update: Peony-Glycyrrhiza Decoction (PGD) for Antipsychotic-induced Hyperprolactinemia in Patients With Schizophrenia [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of Peony-Glycyrrhiza Decoction (PGD) for antipsychotic-induced hyperprolactinemia in schizophrenia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperprolactinemia
• Schizophrenia

Drugs mentioned

• Peony-Glycyrrhiza Decoction (PGD)

Snippet

Sponsor: The University of Hong Kong | Conditions: Schizophrenia, Schizophrenic Disorder | Phase 2 | Status: COMPLETED